Latest Content

Going to a social event two weeks ago gave me perspective on my cancer experience and took me back to my childhood when I never dreamt I’d grapple with the disease.

Until you’re faced with something like cancer some things you thought important become trivial while the under-appreciated become cherished.

The Beamion LUNG-1 study showed that first-line Hernexeos had benefit for patients with HER2-mutated NSCLC.

Dr. Francesca Palandri discusses anemia in myelofibrosis, its impact on survival and quality of life, and the potential of Ojjaara for patients.

Exercise, as an expert explained to CURE, can have a significant positive impact on long-term outcomes for patients with cancer.

When you’re living with a hereditary cancer syndrome, where you get your information matters just as much as the information itself.

Stage 2 lymphoma is treatable. Diagnosis and treatment depend on subtype, but most patients achieve excellent outcomes with modern therapies.

The FDA has approved Revuforj for relapsed or refractory acute myeloid leukemia with an NPM1 mutation.

CURE spoke with Dr. Surbhi Sidana about the recently approved antibody-drug conjugate Blenrep for multiple myeloma.

Combining Rituxan with Mavenclad or Zelboraf upfront can extend remissions safely and should become standard first-line therapy for hairy cell leukemia.

The FDA has granted fast track designation to MT-125 for the treatment of patients with glioblastoma.

The FDA approved Blenrep with Velcade and dexamethasone for relapsed or refractory multiple myeloma.

What you need to know about stomach cancer, also known as gastric cancer.